Voyager Therapeutics, Inc. — FY2017 Form 10-K
Reporting period: Fiscal year ended December 31, 2017. This is an annual filing, not a quarterly report; selected unaudited quarterly data are also included. Voyager is a clinical-stage gene-therapy company with no approved products or product-sales revenue.
Financial performance and position
| Metric | FY2017 | FY2016 | Change / context |
|---|---|---|---|
| Collaboration revenue | $10.1 million | $14.2 million | Down 29%; entirely from Sanofi Genzyme |
| Research and development expense | $62.3 million | $42.2 million | Up $20.0 million |
| General and administrative expense | $19.7 million | $13.3 million | Up $6.5 million |
| Operating loss | $71.9 million | $41.3 million | Loss widened |
| Net loss | $70.7 million | $40.2 million | Loss widened 76%; basic and diluted loss per share was $2.64 versus $1.59 |
| Operating cash flow | $(61.4) million | $(42.5) million | Cash use increased with operating expenses |
| Cash, cash equivalents and marketable securities | $169.1 million | $174.4 million | At December 31; excludes the subsequent AbbVie payment |
| Working capital | $155.9 million | $165.0 million | At December 31 |
Revenue and margins are not indicative of a commercial business: the company had no product sales, and the filing does not provide a meaningful product margin. FY2017 investing cash flow was $(3.7) million and financing cash flow was $59.9 million, primarily from the November share offering, which generated $58.0 million net. The company reported no material debt balance; it did report $26.6 million of operating-lease commitments as of year-end and a $1.0 million non-current liability related to research and development funding.
Fourth-quarter 2017 collaboration revenue was $6.3 million and net loss was $11.8 million, compared with $2.4 million and $14.7 million, respectively, in Q4 2016. The 2017 quarter included $5.5 million of revenue recognized after Sanofi Genzyme declined its Parkinson’s-program option.
Material changes and business developments
- R&D spending rose as the company advanced its Parkinson’s program and expanded preclinical work, staffing and facilities. Higher external R&D costs were the largest stated driver.
- Sanofi Genzyme declined its option for ex-U.S. VY-AADC rights in October 2017. Voyager retained global rights but forfeited up to $105 million in related regulatory and commercial milestones.
- Voyager raised $58.0 million net in a November 2017 public offering. Shares outstanding were 31.6 million at year-end.
- In February 2018, after year-end, Voyager entered a tau gene-therapy collaboration with AbbVie and received a $69.0 million upfront payment. Voyager funds research, IND-enabling work and Phase 1 activities; AbbVie may later exercise development and license options. Potential milestone payments and royalties are contingent, not assured revenue.
Outlook, commentary and risks
- Management expected year-end cash and securities plus the AbbVie upfront payment to fund operating and capital needs into 2020. The company expects significant losses and rising expenses and may need additional financing; no profitability or product revenue is forecast in the filing.
- Voyager planned to dose the first patient in its pivotal Phase 2-3 VY-AADC program in mid-2018. It estimated Phase 2 top-line data in the second half of 2020, Phase 3 enrollment beginning in the first half of 2019 and Phase 3 top-line data in the first half of 2022. These are management expectations, not guarantees.
- Interim, open-label Phase 1b data covered 15 patients across three small dose cohorts. Cohort 2 showed a 3.5-hour mean improvement in diary on-time without troublesome dyskinesia at 18 months; the filing cautions that early and uncontrolled results may not predict placebo-controlled pivotal-trial outcomes. A separate seven-patient posterior-delivery study reported approximately 50% average putaminal coverage and no reported serious adverse events at the time of filing.
- VY-AADC received FDA fast track designation in 2018. The filing says designation does not guarantee faster review or approval. The company submitted an IND in December 2017 for VY-AADC made using its baculovirus/Sf9 process; the IND became effective. Comparability to the earlier HEK293-manufactured product remains an important execution point.
- Management planned two additional IND filings in 2019 from its ALS, Huntington’s and Friedreich’s ataxia programs. These programs were preclinical; timelines and candidate selection remained uncertain.
- Key risks include clinical efficacy and safety uncertainty, invasive brain-surgery delivery and procedure-related harms, manufacturing scale-up and comparability, reliance on contract manufacturers and delivery equipment, regulatory delays, intellectual-property and collaboration risks, competition, and future capital needs. One Phase 1b patient had pulmonary embolism and related arrhythmia attributed by investigators to the procedure and immobility; DVT prevention was added.
- Adoption of the new revenue standard in 2018 was expected to increase deferred revenue and reduce accumulated deficit by approximately $18–23 million on January 1, 2018, subject to final assessment. This is an accounting transition, not new cash or operating revenue.
Most important facts for investors to verify
- Whether pivotal VY-AADC trials start and enroll on schedule, and whether blinded, placebo-controlled results confirm the small open-label study’s apparent benefit.
- Longer-term safety, procedure-related risk, durability and the clinical relevance of delivery-coverage results.
- Manufacturing comparability, quality and supply at clinical and commercial scale using the baculovirus/Sf9 process.
- Actual cash burn and runway against management’s “into 2020” estimate, including spending obligations under the AbbVie collaboration.
- Whether AbbVie or Sanofi Genzyme exercises options and whether any contingent milestones or royalties become payable; do not treat headline potential payments as committed funds.
- The final effect of revenue-standard adoption and the continuing impact of collaboration revenue timing on reported results.